ArticleJournal of Korean medical science2023
Vaccine Effectiveness Against Severe Disease and Death for Patients With COVID-19 During the Delta-Dominant and Omicron-Emerging Periods: A K-COVE Study.
Article in Journal of Korean medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Integrated Clinical and Social Impacts of the COVID-19 Pandemic in Korea: A Combined Systematic and Narrative Review.Journal of Korean medical science · 2026Pooled it
- New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.Immunity, inflammation and disease · 2024Pooled it
- SARS-CoV-2 surveillance and vaccine effectiveness among dental healthcare workers during the omicron surge.Scientific reports · 2026Article
- Severe COVID-19 in the Republic of Korea: Epidemiology, Risk Factors, Therapeutics, and Prognostic Models From Nationwide Data.Journal of Korean medical science · 2026Review
- Effect of COVID-19 vaccine in adults infected with the Delta variant of SARS-CoV-2: a retrospective cohort study.Journal of thoracic disease · 2024Article
- Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose.Vaccine: X · 2024Article
- COVID-19 Mortality and Severity in Cancer Patients and Cancer Survivors.Journal of Korean medical science · 2024Article
- Development and Validation of a Robust and Interpretable Early Triaging Support System for Patients Hospitalized With COVID-19: Predictive Algorithm Modeling and Interpretation Study.Journal of medical Internet research · 2024Article
- Article
- Perioperative Respiratory-Adverse Events Following General Anesthesia Among Pediatric Patients After COVID-19.Journal of Korean medical science · 2023Article
- Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.Journal of Korean medical science · 2023Observational
- The Impact of SARS-CoV-2 Immune Status and Societal Restrictions in Controlling COVID-19 across the World.Vaccines · 2023Review
- Article
- Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022.Journal of Korean medical science · 2023Article
- The Crucial Role of COVID-19 Vaccination in Preventing Severe Illness and Death: Evidence From a Korean Perspective.Journal of Korean medical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
National cohort data collected during the coronavirus disease 2019 (COVID-19) delta and omicron periods in Korea revealed a lower risk of severe infection in recipients of three doses of the COVID-19 vaccine (adjusted odds ratio [aOR], 0.05-0.08). The risk of death was reduced during the omicron period compared to the delta period (aOR, 0.75; 95% confidence interval, 0.67-0.84).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.